De-conglomeration nationJohnson & Johnson takes a page out of GE’s book, breaking up its 135-year old pharmaceutical company.
- J&J is splitting into two in its biggest corporate shake-up yet, spinning off its consumer division to focus on developing new pharmaceuticals.
- Turns out drugs bring in more cash than shampoo (shocker). Its commercial side is set to generate $15bn this year compared to the $77bn the medical arm will rake in.
- GE (GE) became 3 earlier last week, followed in quick succession by both J&J and Toshiba (6502) – looks like the days of the industrial conglomerate are numbered.
JNJ releases strong Q2 earningsJohnson & Johnson shares releases its latest earnings report with a move into positive territory in the pre-market after the pharma giant beat forecasts and hiked its earnings guidance, but shares still open in the red and stay flat for the week.
Johnson & Johnson, the parent of one of the world’s leading vaccines, is seeing all its hard work pay off with Q2 earnings that beat expectations and an upwardly revised full-year guidance. J&J beat on both the top and bottom lines, reporting Q2 earnings of $2.48 per share on revenue of $23.31 billion, compared to expectations of $2.27 in earnings per share on $22.21 billion in revenues. Its pharmaceutical business, which created its single-shot vaccine, brought in $12.59 billion in the quarter, up 17.2% from the same period the year before.
Global COVID vaccine sales reached $164 million over the quarter, and the company is now expecting that number to increase to $2.5 billion by the end of the year. J&J also raised its revenue and earnings guidance for the full year, now expecting a full-year profit of $9.50 to $9.60 per share, up from a previous forecast of $9.30 to $9.45 per share.
J&J beat earnings expectations on vaccine blowoutJohnson & Johnson release Q1 earnings, reporting $100 million in quarterly sales from its COVID-19 vaccine. It’s not been a bad year so far, though clotting concerns are holding back any big price boost.
The company reported earnings of $6.20 billion, or $2.32 per share; compared to $5.80 billion or $2.17 per share in Q1 of last year. Adjusted earnings sat at $2.59 per share compared to expectations of $2.34 per share. Revenue was up almost 8% to $22.32 billion, and the company reported $100 million in Q1 sales of its Covid vaccine - although this is currently on hold in the U.S. while health regulators investigate a rare blood-clotting issue.
Last week, the Food and Drug Administration (FDA) asked states to temporarily halt the rollout of the Johnson & Johnson vaccine after reports came out of at least six women in the U.S. developing a rare blood-clotting condition that left one woman dead. The head of the FDA vaccine division said that this could be a similar reaction to the Astrazeneca vaccine concerns, which have seen the Astrazeneca option suspended in many countries. J&J lost 1.34% on the warning, although it pointed out that that no clear causal relationship has yet been found between these rare blood clots and its Covid-19 vaccine. The firm is working closely with regulators and experts to assess the data.
Johnson & Johnson still expects to deliver 100 million doses in the first half of the 2021 should the blood-clot investigation “go well”, and CFO Joseph Wolk said:
“We remain very confident and we’re hopeful the benefit-risk profile will play out.”
He also said that he’s expecting the U.S. to make its decision by the end of the week after a CDC panel meets on Friday 23 April to make a recommendation. It’s not clear if the pause will impact the company’s ability to deliver 100 million vaccines by June, especially considering the manufacturing obstacles it’s already facing after a plant run by Emergent BioSolutions ruined 15 million doses of the J&J vaccine a few weeks ago.